Firstly, because HER2 is also a frequently affected protein in this type of cancer, but also because acquired resistance to treatments occurs frequently in BC, if not the opposite, with patients classified as HER2+ that do not respond as expected to targeted therapy. The gene discussed is ERBB2; the disease is cancer.